Urgency to Expand SGLT2i Use in HF Heightened by More DELIVER Data
MedPage Today,
Meeting Coverage > HFSA Analyses continue to support wider adoption of dapagliflozin, researchers say by Nicole Lou, Senior…
Meeting Coverage > HFSA Analyses continue to support wider adoption of dapagliflozin, researchers say by Nicole Lou, Senior…
This transcript has been edited for clarity. Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE: Welcome and thank you for joining…
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a drug class beneficial for treating type 2 diabetes, kidney disease…
This transcript has been edited for clarity. Silvio Inzucchi, MD: Welcome to Medscape InDiscussion.